Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER region.

ABSTRACT: Ebola virus (EBOV) in humans causes a severe illness with high mortality rates. Several strategies have been developed in the past to treat EBOV infection, including the antibody cocktail ZMapp, which has been shown to be effective in nonhuman primate models of infection ¹ and has been used under compassionate-treatment protocols in humans ² . ZMapp is a mixture of three chimerized murine monoclonal antibodies (mAbs)^3-6 that target EBOV-specific epitopes on the surface glycoprotein^7,8. However, ZMapp mAbs do not neutralize other species from the genus Ebolavirus, such as Bundibugyo virus (BDBV), Reston virus (RESTV) or Sudan virus (SUDV). Here, we describe three naturally occurring human cross-neutralizing mAbs, from BDBV survivors, that target a

SUBMITTER: Flyak AI 

PROVIDER: S-EPMC6030461 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature